Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), announces the award of 35,697 deferred share units (" DSUs ") to Marvel's three independent directors, in lieu of cash payment for directors' fees. The DSUs will all vest on October 31, 2026. Vested DSUs shall be settled upon... Read More

Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is announcing that, further to the Company's press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that it will be accelerating the expiry date of the warrants issued in relation... Read More

Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. ( collectively "Marvel" or the "Company" ), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent... Read More

Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), announces the award of 142,987 deferred share units (" DSUs ") to two of Marvel's directors, in lieu of cash payment for directors' fees. The DSUs will all vest on July 31, 2026. Vested DSUs shall be settled upon the directors'... Read More

Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), announces that, further to its press releases of March 28, 2025 and May 2, 2025, it has closed its non-brokered private placement (the " Offering "). Pursuant to the Offering, the Company issued an aggregate of 8,150,000 units (the "... Read More

Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that, further to its press release of March 28, 2025 and subject to approval of the TSX Venture Exchange (the " TSXV "), it has closed the second tranche of its non-brokered private placement of up to 12,000,000... Read More

Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) , and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the second final data set from its preclinical Rett syndrome study conducted in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBraiN Institute. The study evaluated... Read More

Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp . (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11 th , 2025. Dr. Mark Williams, Chief Science Officer of Marvel, will present... Read More

Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF ), and its wholly owned subsidiary, Marvel Biotechnology Inc. ( collectively "Marvel" or the "Company" ), is pleased to announce that it has been invited to present its latest research findings at the Alzheimer's Association International Conference (AAIC) , taking place in July 2025. The Company will present preclinical... Read More

Calgary, Alberta--(Newsfile Corp. - March 28, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that, subject to approval of the TSX Venture Exchange (the " TSXV "), it has closed the first tranche of a non-brokered private placement of up to 12,000,000 units (the " Units ") at a price of $0.125 per... Read More

Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for its lead compound, MB-204, as a potential treatment for Rett Syndrome. This decision follows strong... Read More

Calgary, Alberta--(Newsfile Corp. - March 13, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. The study evaluated MB-204, Marvel's lead compound (10 mg/kg oral once daily), in... Read More

Calgary, Alberta--(Newsfile Corp. - March 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the "Conference" ) taking place at the Metro Toronto Convention Centre, on May 5 and 6, 2025.... Read More

Calgary, Alberta--(Newsfile Corp. - January 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce that the Chinese patent office has issued a notice of allowance for its lead compound MB-204. This is the first allowance worldwide for this family. "We are pleased with this allowance of... Read More

Calgary, Alberta--(Newsfile Corp. - January 7, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement of common shares of ‎the Company (each a " Common Share ") at a price of $0.15 per Common Share for gross ‎proceeds of a minimum of $1,935,000 and up to a maximum of $2,500,000 (the " Offering ").‎ It is... Read More

Calgary, Alberta--(Newsfile Corp. - November 26, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), are pleased to share additional data from its ongoing preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. Marvel also announces plans to engage with the FDA to discuss these... Read More

Calgary, Alberta--(Newsfile Corp. - November 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it has been awarded the Alberta Innovates AICE Validates grant, securing $300,000 in funding to support the preclinical validation of MB204 as a treatment for Alzheimer's disease. This... Read More

Calgary, Alberta--(Newsfile Corp. - November 7, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its study on MB204, as a potential new treatment for Rett syndrome. The study, conducted by experts at the iBraiN Institute in Tours (France), demonstrated that chronic... Read More

Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the... Read More

Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. ( collectively the "Company" or "Marvel"), is pleased to announce it has entered a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model (FMR1) of Fragile X syndrome (FXS). Autism and FXS are closely related,... Read More

Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), announce that, effective July 23, 2024, its board of directors approved the grant of incentive stock options (the "Options" ) to certain directors and officers to acquire an aggregate of 1,475,000 common shares in the capital of the... Read More

Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce the extension of its collaboration with Drs. Julie Le Merrer and Jerome Becker, lead investigators at the iBraiN Institute in Tours France. Building upon the promising results using MB204 in... Read More

Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has closed its non-brokered private placement unit offering (the " Offering "). The offering resulted in the issuance of 5,000,000 units... Read More

Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to highlight the recently published paper "Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice" by a member of its scientific advisory board, Dr. David Blum and colleagues (PMID... Read More

Calgary, Alberta--(Newsfile Corp. - June 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), wishes to announce that, further to Marvel's May 16, 2024 press release announcing the Company's non-brokered private placement unit offering (the " Offering "), the TSX Venture Exchange (" TSXV " or the " Exchange ") has... Read More

Calgary, Alberta--(Newsfile Corp. - May 16, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units (the " Units ") at a price of $0.10 per Unit for gross proceeds of up to $1,000,000 (the " Offering "). Each Unit will be comprised of one... Read More

Calgary, Alberta--(Newsfile Corp. - March 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) , and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") , today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, a world expert on Tau pathology. Tau phosphorylation is a process where phosphates... Read More

Calgary, Alberta--(Newsfile Corp. - March 12, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBrain Institute in Tours, France. The study demonstrated that a single oral dose of MB-204 can restore... Read More

Calgary, Alberta--(Newsfile Corp. - February 20, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce it has begun testing MB-204 in the Oprm1 mouse model of autism in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBrain Institute, Tours, France. "We are going to test... Read More

Calgary, Alberta--(Newsfile Corp. - January 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce the Company has closed a non-brokered private placement (the " Offering ") of unsecured convertible debentures (each, a " Debenture "). The closing was comprised of an aggregate of Cdn.$500,000 of... Read More

Calgary, Alberta--(Newsfile Corp. - January 8, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study the acute effect of MB-204 on Tau protein phosphorylation in mice. Abnormal tau phosphorylation is a hallmark of... Read More